(Image source from: assettype.com)
Moscow’s Mayor expressed hope that the majority of the Russian’s capital residents would be vaccinated against the coronavirus in several months.
The Russian health ministry has registered the first vaccine against COVID-19 in the world, named Sputnik-V on August 11.
The first batch of the Sputnik-V vaccine against the novel coronavirus has been released into the civil circulation and regular deliveries are planned in the nearest future. The information was given by the Russian Health Ministry.
The Sputnik-V vaccine was jointly developed by the Gamaleya National Research Center and the Center for Epidemiology and Microbiology of the ministry of health of Russia. The first batch of the Sputnik-V vaccine for the prevention of coronavirus has passed the necessary quality tests in the laboratories of Roszdravnadzor and has been released into civil circulation.
The Russian health ministry registered the first vaccine against COVID-19, named Sputnik-V on August 11. The vaccine is created by Moscow’s Gamaleya Research Institute of Epidemiology and Microbiology was fast-tracked for approval after providing capable of building up immunity against the virus in the human testing.
Moscow Mayor Sergey Sobyanin expressed hope on Sunday that the majority of the Russia’s capital residents would be vaccinated against the coronavirus within several months.
According to the health ministry, the delivery of the first batches of the Russian vaccine to the country’s region is planned in the nearest future.
Meanwhile, according to the preliminary results published in the Lancet Journal, Russia’s COVID-19 vaccine Sputnik-V appears to be safe without any serious adverse effects and has developed long-term antibody response in humans during the clinical trials.
Results from the two early phased Russian non-randomized vaccine trials showed that the formulations of the two-part vaccine, Sputnik-V, have a good safety profile with no serious adverse events detected over 42 days among 76 subjects, and induces antibody responses in all participants within 21 days.
Secondary outcomes from the trials also suggest that the vaccines also produced a T cell response within 28 days that provide long term immunity.
Russia is also planning to start phase 3 human trials in India, Brazil, the Philippines, and other countries this month as it believes India has the largest manufacturing capacity for producing the coronavirus vaccine.
By Gayatri Yellayi